Sun 11/18/2018 15:31 ET
DJIA25413.22124.520.49%TELCO170.142.211.30%GOLD1222.0022.851.87%Shanghai2679.1110.980.41%
S&P 5002736.276.020.22%BANKS448.240.000.00%OIL56.830.370.65%BITCOIN5543.3342.680.77%
NASDAQ7247.8710.870.15%PHARM586.330.000.00%US/EU1.140.000.01%Futures2742.257.680.28%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Daxor Corp - DXR   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DXR
  
From: SunTzu772 (Rep: 1078) reply to SunTzu772Date: 11/07/2018 10:30
Forum: Daxor Corp - Msg #107Thread #674044798 (Rec: 1)
7.49 US Army contract...difficult to get any bigger.

----

Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care

----

November 07, 2018 08:30 ET | Source: Daxor Corporation
----

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Army has selected it for a contract award to develop a blood volume analyzer for improving combat casualty care.
----
The selection was made under the Defense Department’s Small Business Innovative Research (SBIR) program. The contract award will be to develop and demonstrate a prototype blood volume analyzer suitable for military use leveraging Daxor’s technology and experience with blood volume measurement devices. “Hemorrhage is the primary cause of death in about 30% of injured soldiers,” said Michael Feldschuh, CEO of Daxor Corporation. “Direct blood volume measurement has been shown to improve outcomes in a broad range of acute and chronic medical conditions. Our existing technology platform and patent portfolio is an ideal foundation for developing a rapid, rugged, portable blood volume analyzer that can improve prehospital resuscitation on the battlefield, potentially saving many lives.”

----
"This is an exciting additional opportunity to push our research and development program forward,” says Jonathan Feldschuh, Chief Scientific Officer. “We are focused on making volume measurement easier and quicker to perform, whether in a hospital lab, on the battlefield, or at the patient bedside.”
This is a first-time award for Daxor. SBIR contracts are designed to stimulate innovation by companies to develop technologies and solutions that meet critical Army needs. SBIR programs benefit the Department of Defense (DoD) and the private sector and support the nation’s economic growth.
----

About Daxor Corporation
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com.



------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------



Reply to SunTzu772 - Msg #86 - 10/30/2018 10:50

5.34 major news 790k float - New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

----

GlobeNewswire•October 30, 2018

----
Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality
----

NEW YORK , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by blood volume measurement with the BVA-100 blood volume analyzer, compared to propensity-matched controls.
----

“This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes. Heart failure represents one of the largest areas of healthcare spending and one of the most significant treatment challenges for approximately 6 million US patients, which is expected to double as the population ages,” commented Michael Feldschuh, CEO of Daxor. “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”
----

Treatment guided by the BVA-100 blood volume analyzer resulted in a statistically significant decrease in rehospitalization (12.2 percent vs. 27.7 percent, p<0.001), 30-day mortality (2.0 percent vs. 11.1 percent, p<0.001) and 365-day mortality (4.9 percent vs. 35.5. percent, p<0.001), compared to a propensity score control. Further, an analysis of 30-day readmission by diagnosis showed fewer heart failure readmissions (6.1 percent vs. 20.2 percent, p<0.001) and fewer cardiac non-heart failure admissions (1.6 percent vs. 3.9 percent, p<0.001).
----

"The results of this outcome study demonstrate without question that accurate blood volume measurement substantially improves the physician’s ability to prescribe decongestion therapy that will result in significantly better outcomes in acute heart failure, particularly with regard to rehospitalization and mortality,” said John E. Strobeck, M.D., Ph.D., Director, Heart-Lung Consultants, Inc., Hawthorne, NJ and lead author of the study. “These results clearly show that BVA measurement has a one-to-one relationship in achieving meaningful improvements in clinical and resource-use outcomes in patients hospitalized for acute heart failure.”

----
Total blood volume, red blood cell volume and plasma volume were measured using Daxor’s BVA-100, an I-131 labeled albumin indicator dilution technique that is unique to the BVA-100. Patients were assigned a decongestion and treatment strategy based on the BVA-100 measurement. Propensity score control matching was derived from CMS data matching 10:1 for demographics, comorbidity and year of treatment.

----
https://globenewswire.com/news-release/2018/10/30/1639097/0/en/New-Study-Cites-82-Percent-Mortality-and-56-Percent-Rehospitalization-Reductions-30-Days-After-Therapy-Guided-by-Daxor-s-BVA-100-Blood-Volume-Analyzer-in-Acute-Heart-Failure-Patien.html
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreDXR: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DXR
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.